Concepedia
Statistics
Publications
4
Citations
82
H-Index
Active since
2017
Affiliations
PAREXEL International (United Kingdom)(Current)
AstraZeneca (United Kingdom)
Pfizer (United States)
Samuel Large is an author at PAREXEL International (United Kingdom).
Publications per year
2017–2021
Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer
Evelina Bertranou, Carolyn Bodnar, Viktor Dansk et al. · Journal of Medical Economics · 2017 · 40 citations
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy
Mark H. Rozenbaum, Samuel Large, Rahul Bhambri et al. · Journal of Comparative Effectiveness Research · 2021 · 19 citations · Full text
Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective
Rui Martins, Melodi Koşaner Kließ, Craig Beck et al. · Journal of health economics and outcomes research · 2021 · 12 citations · Full text
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
Claire Telford, Evelina Bertranou, Samuel Large et al. · PharmacoEconomics - Open · 2019 · 11 citations · Full text
1–4 of 4